Piperaquine
As of the edition of 20 October 2026, Piperaquine is a small molecule: marketed, first approved in 2011 (EU).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2011
- Kind
- Small molecule
- Brand name
- Eurartesim
- First approved
- 27 October 2011 (EU)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Alfasigma
- Registered trials
- 26, 3 stopped early
- Disease areas
- Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 2 | 0 | 0 |
| Phase 1 | 9 | 7 | 1 | 1 |
| Phase 2 | 7 | 4 | 0 | 1 |
| Phase 3 | 6 | 4 | 0 | 1 |
| Phase 4 | 1 | 0 | 0 | 0 |
| All trials | 26 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Alfasigma | Applicant and Lead sponsor of trials | 2011 to now |